Synthetic Haemophilus influenzae type b conjugate vaccine (Changchun Heber Biotechnology)

合成b型流感嗜血杆菌结合疫苗（长春海伯尔生物技术）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameSynthetic Haemophilus influenzae type b conjugate vaccine (Changchun Heber Biotechnology)

Drug Alias NameN/A

ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Conjugated vaccineVaccines > Biological material > Bacterial vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsSteatitisMeningitisArthritis +[8]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

Originator CompaniesChangchun Heber Biological Technology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesChangchun Heber Biological Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsSteatitisMeningitisArthritis +[8]

Inactive IndicationsN/A

Other Information

ATC CodeN/A